Scope of scientific reflections expands as ANGANY advances clinical development of First-in-Class biologics
ANGANY recently hosted members of its Scientific Advisory Board in beautiful Quebec City. This was the company’s first in-person meeting of its SAB. Participants included members of the SAB, some or their collaborators and several members of ANGANY’s executive team. This meeting of the SAB could not be timelier as the very first clinical results of ANGANY’s ANG-101, the company’s candidate-therapeutic against human allergy to cats, were just communicated by the investigation team from the Royal Brompton Hospital where the First-in-Human study of an ANGANY product is being conducted. The results of the “Sentinel” subjects were reviewed and this indeed powered very insightful discussions on the new realm of allergy immunotherapy ANGANY’s innovative eBioparticle-Potentiated Immunotherapy™ platform is bringing about. Issues regarding optimization of future therapeutic candidates, clinical and regulatory development as well insights from ANGANY’s veterinary development program made for substantive scientific exchanges.
Dr. Véronique Gomord, ANGANY’s Chief Innovation Officer states, “Over the past few years, we have accumulated a remarkable depth of preclinical data for several therapeutic candidates. It is very encouraging to see these starting to translate into clinical reality. I really enjoyed the opportunity to share with our esteemed colleagues on how best to bring all this forward from this point.”
Ms. Christine Guillen, CEO of ANGANY adds, “We are grateful to be able to count on some of the world’s top scientific authorities in the world of allergy to assist us in pushing forward with an approach to allergy immunotherapy that departs from more than 100 years of desensitization. Our platform biotechnology forces a rethink of how we view the treatment of allergy and even we could intervene for prevention.”
